Komori
M

MEDICAL SYSTEM NETWORK Co.,Ltd.

4350RetailMicro cap
527JPY-0.9%
★ Watch (sign-up required)
Price history
¥527Latest-15.0%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group operates a regional pharmacy network business as its core business, alongside leasing and equipment-related operations, food services and other businesses. Key group companies include the Hananoha series, Felsen Pharma, Medilogy Net and Pharmo. With digitalization and expansion of the pharmacy network as its medium- to long-term objectives, the Group is working to increase the number of pharmacies it supports and promote logistics and digital transformation. For the fiscal year ending March 2026, consolidated net sales were ¥132,186 million and segment profit was ¥3,313 million. Key financial indicators include total assets of ¥80,100 million, net assets of ¥17,413 million and 4,014 employees. Medium- and long-term targets include operating profit of ¥5 billion, ROE of 11% and support for 25,000 facilities by the fiscal year ending March 2030.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 18
PBR
0.94How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
-0.7%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥16bnShare price × number of shares. The value of the entire company.
Equity ratio
21.4%The proportion of assets funded by money that does not have to be repaid.
Operating margin
0.4%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
6.2%The average annual growth in sales over the past three years.
Forward P/E
16.15Forward P/E based on estimated earnings for the next fiscal year.
What to watch next
Specific disclosure of growth and monetization initiatives and KPI progress under the Seventh Medium-Term Management Plan (fiscal years ending March 2027 through March 2030)
Fiscal year ending March 2027 onwardImpact MediumLikelihood Medium
Continued expansion in the number of stores using the digital shift (currently 6,658 stores) and its impact on order-taking and prescription-related KPIs
Impact MediumLikelihood High
Expansion in the number of customer stores served by the pharmaceutical logistics business (メディロジネット; currently 3,690 stores), together with confirmation of improvements in supply capacity and profitability
Impact MediumLikelihood Medium
Depending on the details of revisions to the drug price schedule and dispensing fees, prescription unit prices and dispensing revenue may fall outside the expected range, in either direction
When the regulatory revisions take effect, mainly in fiscal years and mid-cycle yearsImpact HighLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 55.4%
Listed holders 55.4%Everyone else 44.6%
合同会社エスアンドエス9.28%
沖中 恭幸8.40%
The Master Trust Bank of Japan, Ltd. (Trust Account)7.77%
秋野 治郎7.45%
光通信ＫＫ 投資事業有限責任組合6.99%
MSI P CLIENT SECURITIES3.85%
Custody Bank of Japan, Ltd. (Trust Account).3.11%
メディカルシステムネットワーク従業員持株会2.94%
2 other listed holders5.60%
Who owns it
HolderOwnership (%)
合同会社エスアンドエス9.28
沖中 恭幸8.40
The Master Trust Bank of Japan, Ltd. (Trust Account)7.77
秋野 治郎7.45
光通信ＫＫ 投資事業有限責任組合6.99
MSI P CLIENT SECURITIES3.85
Custody Bank of Japan, Ltd. (Trust Account).3.11
メディカルシステムネットワーク従業員持株会2.94
2 other listed holders5.60
This company's documents
Filings
Timely disclosures